Oculis Holding AG
Clinical-stage biopharma developing therapies for ophthalmic and neuro-ophthalmic diseases.
OCS | IC
Overview
Corporate Details
- ISIN(s):
- CH1242303498 (+1 more)
- LEI:
- 5067005370C2KK324336
- Country:
- Switzerland
- Address:
- Bahnhofstrasse 7, 6300 Zug
- Website:
- https://www.oculis.com/
- Sector:
- Manufacturing
Description
Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-22 10:00 |
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor …
|
English | 11.4 KB | ||
| 2025-09-09 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 952 bytes | ||
| 2025-09-04 19:00 |
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
|
English | 6.5 KB | ||
| 2025-09-03 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 950 bytes | ||
| 2025-09-01 10:00 |
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Op…
|
English | 17.7 KB | ||
| 2025-08-28 10:00 |
Oculis to Participate in Upcoming September Investor Conferences
|
English | 6.1 KB | ||
| 2025-08-25 10:00 |
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-R…
|
English | 13.2 KB | ||
| 2025-08-21 22:05 |
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
|
Icelandic | 20.6 KB | ||
| 2025-08-21 22:05 |
Oculis Reports Q2 2025 Financial Results and Provides Company Update
|
English | 18.3 KB | ||
| 2025-08-12 10:00 |
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtu…
|
English | 4.2 KB | ||
| 2025-08-01 10:00 |
Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF
|
Icelandic | 8.1 KB | ||
| 2025-08-01 10:00 |
Oculis Upsized Loan Facility to Access up to CHF 100 million
|
English | 7.1 KB | ||
| 2025-07-09 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 948 bytes | ||
| 2025-06-09 22:05 |
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 940 bytes | ||
| 2025-06-05 10:00 |
Oculis birtir niðurstöður aðalfundar 2025
|
Icelandic | 7.7 KB |
Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oculis Holding AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oculis Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
